|Systematic (IUPAC) name|
Filaminast (WAY-PDA 641) was a drug candidate developed by Wyeth-Ayerst.:Table 2 It was a phosphodiesterase 4 inhibitor (PDE4 inhibitor) and an analog of rolipram, which served as a prototype molecule for several development efforts.:668, 678 It was discontinued after a Phase II trial showed that its therapeutic window was too narrow; it could not be dosed high enough without causing significant side effects (nausea and vomiting), which was a problem with the rolipram class of molecules.:678
- Filaminist entry at Pubchem
- Halpin DM. ABCD of the phosphodiesterase family: interaction and differential activity in COPD. Int J Chron Obstruct Pulmon Dis. 2008;3(4):543-61. PMID 19281073 PMC 2650605
- Giembycz, M A (2008). "Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking?". British Journal of Pharmacology 155 (3): 288–90. doi:10.1038/bjp.2008.297. PMC 2567889. PMID 18660832.
- McKenna, JM and Muller, GW. Medicinal Chemistry of PDE4 Inhibitors. Chapter 33 in Cyclic Nucleotide Phosphodiesterases in Health and Disease, Eds Joseph A. Beavo et al. CRC Press, Dec 5, 2006 ISBN 9781420020847